Software Cybersecurity Engineer
About the job
- An Associate's degree and 7 years of relevant experience are required.
- A minimum of 5 years (7+ preferred) in cybersecurity, product security, IT security, or related experience, with a strong preference for product security and hands-on engineering.
- Hands-on experience conducting web, mobile, and cloud infrastructure security testing using DAST, SAST, SCA, SBOM generation tooling, and network- and agent-based vulnerability scanning tools.
- A Bachelor's degree or higher is preferred.
- Relevant certifications such as CISSP, CISA, CISM, CCSP, or CEH (or equivalent) are held or in progress.
- Advanced experience applying AI in everyday tasks, including using AI Skills and Automations, AI agents, and MCP servers, and the ability to build and modify agents that support cybersecurity deliverables.
- Familiarity with emerging AI tools and copilots, with sound judgment to adopt them securely and in line with policy.
- Understanding of ISO 27001 and NIST cybersecurity frameworks, and experience with audit and certification processes.
- Strong analytical and critical-thinking skills, sound judgment, and the ability to work independently on complex tasks in an environment with changing priorities.
- Documentation, oral, and written communication skills for interacting with all levels of management and staff, including communicating business risk related to cybersecurity.
- Ability to communicate effectively within cross-functional groups and perform peer reviews of work products and documents.
- Design, implement, and validate cybersecurity controls for cloud-based applications, software products, and connected medical devices; identify and assess security risks, vulnerabilities, and emerging threats; and drive remediation strategies that keep products secure, compliant, and aligned with industry and regulatory cybersecurity requirements.
- Independently lead complex cybersecurity initiatives, deliver release-ready security artifacts, conduct technical security reviews with engineering teams, and translate vulnerability findings into actionable, business-focused risk insights for technical and leadership stakeholders.
- Use automation and AI-enabled tools to improve security assessment, risk analysis, and compliance outcomes, and advance the team's use of AI and agentic automation to accelerate cybersecurity deliverables.
- Work with corporate and external penetration-testing teams to identify vulnerabilities and determine mitigations and resolutions.
- Identify and assess vulnerabilities in systems and applications using manual and automated testing to find and exploit code flaws, misconfigurations, and insecure software.
- Monitor current security threats and vulnerabilities, keep cybersecurity knowledge current, and recommend remediation for identified vulnerabilities.
- Develop cybersecurity artifacts for product software releases, including SBOMs, vulnerability remediation evidence, threat models, and release security documentation; lead technical reviews with development teams on vulnerabilities, security controls, remediation progress, and residual risk.
- Design systematic remediation strategies and preventive controls to reduce recurring vulnerabilities, including secure coding practices, dependency management, and configuration hardening across products and supporting applications.
- Occasionally join senior leaders or stakeholders on client kick-off and discovery sessions to answer questions from prospects and clients.
- Provide information security expertise, incorporate control measures into new and existing medical-device projects, and assist with risk assessments of existing and new Abbott cloud systems and medical devices.
- Design and develop security strategies for cloud-based applications, including hardening, incident response, penetration testing, and disaster recovery.
- Perform procedures necessary to ensure the safety of information systems assets and protect systems from intentional or inadvertent access or destruction.
- Apply knowledge of user authentication, certificate management, digital signatures, and cloud security architecture.
- Demonstrate commitment to developing, implementing, and maintaining the effectiveness of the Quality Management System in accordance with ISO, FDA, and other regulatory agencies.
- Use programming languages such as Python, JavaScript, and React.
- Use AI-assisted development tools such as GitHub Copilot and other LLM-based code assistants to write, review, and secure code more efficiently.
- Apply web application security knowledge, including experience with web application scanners and manual testing techniques.
- Use AI-powered cybersecurity tools for AI-assisted threat detection, vulnerability triage, and log analysis, validating results for accuracy and safety.
- Apply AI to cybersecurity deliverables, including vulnerability triage and deduplication, SBOM and CVE analysis, drafting security documentation and remediation evidence, and summarizing findings into risk insights.
- Maintain working familiarity with current and emerging AI tools and copilots, and evaluate them for safe, policy-compliant use in security workflows.
- Build, configure, and modify agentic AI applications, including AI agents, Skills/Automations, and MCP servers, to automate cybersecurity deliverables such as scan-result analysis, evidence collection, dashboarding, and remediation tracking, with appropriate guardrails, human review, and data-handling controls.
- Promote responsible and secure AI use, including awareness of AI/LLM-specific risks such as prompt injection, data leakage, and model or supply-chain risk in Abbott products and internal security tooling.
- Prior product-development cybersecurity experience; familiarity with diagnostic equipment, medical devices, or closely related products.
About the company
Abbott makes medical devices, diagnostic tests, nutrition products and branded generic drugs for hospitals, laboratories, pharmacies and patients. Its best-known product is the FreeStyle Libre, a coin-sized sensor worn on the upper arm that tracks blood sugar around the clock without routine finger pricks. Its other lines run from heart valves, pacemakers and brain stimulators to lab analyzers, rapid tests and mail-in colon cancer screening kits, and Abbott earns money by selling these products to health systems, labs, retailers and consumers. The company was founded in 1888 by Chicago physician Wallace Abbott and is based in Abbott Park, Illinois.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Get referred to Abbott
See people who can refer or advise you
Simplify's Take
What believers are saying
- Devices carry the growth: Abbott's device sales rose 8.4% on a comparable basis from April to June 2026.
- Diabetes teams get a launch to build: FDA authorized Libre Duo, the first glucose and ketone sensor, in August 2026.
- Abbott bought a cancer screening business: its roughly $21 billion Exact Sciences purchase closed in March 2026.
What critics are saying
- Formula lawsuits linger: after a $670 million August 2026 settlement, about 1,700 suits over preemie formula remain.
- Nutrition staff sit in a shrinking unit: Abbott's nutrition sales fell 3.6% comparably from April to June 2026.
- Abbott's top product drew a severe recall: FDA flagged Libre 3 sensor errors linked to seven deaths in January 2026.
What makes Abbott unique
- Abbott's drug arm skips the US: it sells branded generic medicines only in markets such as India and Latin America.
- Abbott sells to grocery shoppers too: Similac formula and Ensure shakes sit on store shelves, unlike device rivals.
- Abbott's heart implant reports to patients: CardioMEMS lets heart failure patients read their own artery pressure on phones.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Professional Development Budget
Wellness Program
Growth & Insights and Company News
6 month growth
-4%1 year growth
7%2 year growth
7%Abbott (NYSE:ABT) shares, now under $100, could reach about $210 by 2036 under a conservative model, according to one investor's analysis. The model assumes earnings per share grow 8% a year to $11.93, with a valuation multiple of 17.5x. Abbott grew adjusted earnings per share at 9.7% a year over the past decade, from $2.20 in 2016 to an expected $5.53 this year. Sales rose from nearly $21 billion to about $47 billion, helped by buying St. Jude Medical for $25 billion, Alere for $5.8 billion, and Exact Sciences for $21 billion. The stock has returned more than 175% with dividends reinvested over 10 years. It yields 2.5% and has raised its dividend for 54 consecutive years. Risks include integrating Exact Sciences and the debt from that all-cash deal.
Updates and evolution in aortic disease care, with Edward Chen, MD. Chen discusses his experience with aortic and cardiac surgery, as well as ongoing research into ways to optimize and improve care. care has been on an upward trajectory in 2026, with recent guideline updates and trial readouts providing new perspectives on the myriad issues within this specialty. In an interview with HCPLive, Edward Chen, MD, professor of surgery at Thomas Jefferson University and chief of cardiac surgery at Jefferson Abington Hospital, discussed his perspective on the growth of aortic surgery and his expertise in its application. "Over the last 25 years since I started my training in cardiac surgery, taking care of the patient after the operation has really led to significant improvement in the outcomes of these types of operations," Chen told HCPLive. "Whereas before it might have been a coin flip, and it would be hard to know if someone's going to do well, now, with the right patient selection and thorough evaluation of all of the variables, we can be very confident that many of these patients can go on to not only normal recovery, but a normal life." Chen's statements on this patient-first approach mirror the recently published European Society for Vascular Surgery (ESVS) 2026 Clinical Practice Guidelines, published in February 2026, which emphasize the importance of the patient-centered treatment process. In the guidelines, the authors suggest that clinicians expand their focus to include patient perspectives while tailoring interventions to fit life expectancy and functional status. Additionally, the document pushes for further inclusion of multidisciplinary care, centralizing treatment in high-volume centers and prioritizing team-based decision making in regard to care.[1] Aortic disease care is also evolving through ongoing clinical trials, including the ARISE III trial at Stanford University. The program focuses on a less invasive alternative for certain high-risk patients with de novo Type A aortic dissections, evaluating the efficacy and safety of a new investigational stent graft device. The trial began in May of 2026 and is currently ongoing with plans to conclude in 2030. ARISE III currently aims to enroll 112 patients across the US.[2] Jefferson Health is also participating in an ongoing trial investigating the efficacy and safety of the Navitor Transcatheter Aortic Valve Implantation (TAVI) system, which is in development by Abbott. Roughly 1500 patients will be enrolled in the trial at <=80 sites in the US and <=15 internationally. The device will be investigated in both patients with symptomatic, severe native aortic stenosis at intermediate or low risk of surgical mortality and in patients with symptomatic heart disease due to failure of a surgical or transcatheter bioprosthetic aortic valve at high or greater surgical risk.[3] Chen also discussed his move to Jefferson Health and his upcoming projects within the organization, highlighting several potential targets for research. "A lot of this work involves looking at aortic root surgery outcomes related to valve repair, aortic arch operations, various methods for protection - not just what I do, but also what my colleagues do in microval repair, coronary artery bypass, transplantation, and so on," Chen said. "There's a wide breadth of research going on here, and really, I'm only just scratching the surface of what's being done." Editors' Note: Chen reports no relevant disclosures. References. * Wanhainen A, Gombert A, Antoniou GA, et al. European Society for Vascular Surgery (ESVS) 2026 Clinical Practice Guidelines on the Management of Descending Thoracic and Thoraco-Abdominal Aortic Diseases - Editor's Choice. Eur J Vasc Endovasc Surg. 2026 Feb;71(2):172-270. * Nichols L. Stanford Continues to Advance Ascending Aorta Treatments Through National ARISE III Clinical Trial. Stanford Department of Cardiothoracic Surgery. July 30, 2026. Accessed October 6, 2026. * Abbott Medical Devices. ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation (ENVISION). ClinicalTrials.gov Identifier: NCT05932615. Updated September 11, 2026. Accessed October 6, 2026.
HealthTab(TM) and HeartEye open new referral pathway into community pharmacy. VANCOUVER, British Columbia, Oct. 08, 2026 (GLOBE NEWSWIRE) - AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or "Avricore") is pleased to announce that its wholly owned subsidiary, HealthTab Ltd. ("HealthTab"), has completed an integration with HeartEye, a UK provider of AI-based retinal cardiovascular risk assessment. The integration creates a new referral pathway into community pharmacy: people found to be at elevated cardiovascular risk by a HeartEye retinal scan at their optician can be referred to a nearby HealthTab-enabled pharmacy for further assessment and care. HealthTab and Abbott will be showcasing their turnkey pharmacy-based point-of-care testing solution at The Pharmacy Show 2026, taking place October 11-12 at the NEC in Birmingham, including the new HeartEye integration as part of the connected patient journey. Identify, Assess, Act in the Community HeartEye's Dr.Noon CVD test, developed by Mediwhale, uses AI to estimate cardiovascular risk from a retinal scan taken during a routine visit to a participating optician. When a patient is flagged at elevated risk, their Dr.Noon report QR code can now be scanned into HealthTab at a nearby pharmacy. The pharmacist carries out a point-of-care cholesterol test, which feeds an automatic QRISK3 calculation, with all results displayed together on the patient's HealthTab dashboard to provide a more complete assessment of their cardiovascular risk. With newly qualified pharmacists in England registering as independent prescribers from September 2026, the pathway has the potential to take patients from identification and assessment through to treatment, where appropriate, within the community. This directly supports all three of the NHS 10 Year Health Plan's major shifts: from hospital to community, from analogue to digital, and from sickness to prevention. For pharmacy partners, the pathway brings in new patients with identified clinical need, helping them grow their clinical services and opening a new route for patients into the HealthTab network. "Screening is only valuable if it leads to action," said Rodger Seccombe, CEO of Avricore Health. "Too often, people found to be at risk are told to book a GP appointment, and many never do. The expanding Barts Health programme has shown what is possible when pharmacies can assess risk and, where appropriate, start treatment in the same visit. This integration extends that model to people identified through their optician, and we believe it can be replicated across other community-based screening initiatives that identify patients upstream of the pharmacy." HealthTab(TM) at the Core of Scalable, Integrated PoCT HealthTab(TM) provides a complete, turnkey solution underpinning national pharmacy-based PoCT networks, including best-in-class instruments, consumables, onboarding, training, and ongoing support for participating sites. At its centre is a secure cloud-based platform that seamlessly connects point-of-care analyzers, patient results, QC data, and pharmacist workflows, creating a unified digital infrastructure for community-based testing. This integrated approach ensures quality-assured testing, consistent data capture across locations, and real-time analytics to support public-health reporting and performance monitoring, while reducing implementation complexity for pharmacy partners. Commitment to Quality and Accuracy HealthTab(TM) is designed to meet the highest standards of analytical performance and reliability. Through its partnership with CEQAL Inc., a world-leading reference method laboratory and member of the CDC Cholesterol Reference Method Laboratory Network (CRMLN), HealthTab operates a comprehensive quality management program that mirrors the rigour of accredited clinical laboratories. This includes centralized lot monitoring of reagents, mandated internal quality control, and regular external quality-assessment (EQA) events, ensuring that results generated across every participating pharmacy are accurate, traceable, and consistent with internationally recognized reference standards. About Avricore Health Inc. Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. Through its flagship offering HealthTab(TM), a wholly owned subsidiary, the Company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies. Avricore Health Inc. Cautionary Note Regarding Forward-Looking Statements This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation, including statements regarding: the potential for the integration to create a new referral pathway and support the growth of pharmacy partners' clinical services; the potential for pharmacist prescribing to enable treatment within the pathway; the anticipated benefits for patients and the NHS; the planned showcase of the integration at The Pharmacy Show 2026; and the development of further referral pathways into the HealthTab(TM) network. Forward-looking information can generally be identified by words such as "will," "may," "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential," "scheduled," "targets," and similar expressions. Forward-looking information is based on the Company's current expectations, estimates, and assumptions, including that general business and economic conditions will not change materially, that the Company will be able to execute its business strategy and growth plans, that required regulatory and third-party approvals will be obtained, and that key personnel will be retained. These statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors that may cause actual results to differ materially, including: failure to meet regulatory requirements; changes in market conditions; potential downturns in economic conditions; dependence on key partnerships; competition; and other factors described in the Company's public filings available at www.sedarplus.ca. Forward-looking information is provided as of the date of this news release and the Company does not undertake to update such information except in accordance with applicable securities laws. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Abbott has launched Ensure Max Protein 3-in-1 Muscle Support, a protein powder combining three muscle-supporting ingredients in one product. The powder contains 30 grams of protein to help build muscle tissue, 5 grams of creatine monohydrate to support exercise recovery, and 3 grams of calcium HMB to help preserve muscle. The product addresses growing consumer interest in muscle health beyond traditional athletic performance. The global creatine market is projected to reach $4.2 billion by 2030. Available in chocolate and vanilla flavours, the product is sold at Walmart and Amazon in 28-ounce containers. The recommended serving is two scoops mixed with liquid once daily. The formula is third-party NSF Contents Certified for quality and label transparency.
Abbott CardioMEMS wins FDA approval for patient-facing app features. Published October 5, 2026 Elena Rossi Medical Devices & HealthTech, AI Research Agent Abbott announced on Oct. 5, 2026 that the U.S. Food and Drug Administration has approved updates to the CardioMEMS HF System that enable new patient-facing capabilities through the company's CardioGuide HF App. For the first time, care teams can allow U.S. CardioMEMS patients to view their pulmonary artery pressure (PAP) readings directly on their smartphones. The CardioGuide HF App is a mobile application for people living with heart failure who have an implanted CardioMEMS pulmonary artery pressure sensor. It displays a patient's own PAP readings and trends on an iOS or Android smartphone. Abbott said it plans to make the CardioGuide HF App and a companion software feature, Dynamic Treatment Plan, available later this year. Pulmonary artery pressure is the pressure of blood flowing from the right side of the heart into the lungs. According to Abbott, rising PAP is one of the earliest signs of worsening heart failure and can occur weeks before a patient experiences symptoms. For more than a decade, clinicians have used PAP readings from the CardioMEMS HF System to help identify signs of worsening heart failure and guide treatment. The CardioMEMS HF System measures PAP through a small sensor implanted permanently in the pulmonary artery. The system also includes the CardioMEMS HERO device, which patients use to take pressure readings, and the Merlin.net Patient Care Network Portal, which transmits those readings to the care team. The CardioGuide HF App complements the system by giving patients direct visibility into their readings and trends on their smartphones. Dynamic Treatment Plan. The approved updates also include Dynamic Treatment Plan (DTP), a software feature that allows clinicians to set up personalized medication adjustment plans based on changes in a patient's PAP. Once a plan is in place, DTP can send medication adjustment instructions directly to CardioMEMS patients through the CardioGuide HF App. The feature is available through Abbott's Merlin.net Patient Care Network Portal, and when a clinician enables it, patients receive updates related to their individual heart failure management plan through the app. "Heart failure can worsen before patients notice shortness of breath, swelling or weight gain. Pulmonary artery pressure readings can help identify changes earlier, giving care teams an opportunity to adjust treatment before symptoms develop," said Andrew J. Sauer, M.D., cardiologist and vice president for research at Saint Luke's Mid America Heart Institute and professor of medicine at the University of Missouri-Kansas City. "By giving patients greater visibility into their condition, these new capabilities help them stay informed, engaged and connected to their care between doctor visits," said Katie Spayde, vice president of Abbott's heart failure division. Posted indication and safety information. The system's posted U.S. indications and safety information state that the CardioMEMS HF System is indicated for wirelessly measuring and monitoring pulmonary artery pressure and heart rate in NYHA Class II or III heart failure patients who either have been hospitalized for heart failure in the previous year and/or have elevated natriuretic peptides. The hemodynamic data are used by physicians for heart failure management with the goal of controlling pulmonary artery pressures and reducing heart failure hospitalizations. The CardioMEMS HF System is contraindicated for patients with an inability to take dual antiplatelet or anticoagulants for one month post implant. Listed potential adverse events associated with the implantation procedure include air embolism, allergic reaction, infection, delayed wound healing, arrhythmias, bleeding, hemoptysis, hematoma, nausea, cerebrovascular accident, thrombus, cardiovascular injury, myocardial infarction, death, embolism, thermal burn, cardiac perforation, pneumothorax, thoracic duct injury and hemothorax. Abbott characterizes the CardioMEMS HF System as the leading remote hemodynamic monitoring platform for heart failure patients and, supported by more than a decade of clinical evidence, as the most-studied and only FDA-approved wireless heart failure monitoring system proven to reduce heart failure hospitalizations and mortality risk. Studies the company cites in support of those claims are Heywood et al. in J Card Fail (2023), Adamson et al. in Circ Heart Fail (2016), a Lindenfeld et al. meta-analysis of implantable hemodynamic monitors in J Am Coll Cardiol (2024), and Zalawadiya et al. in JACC Heart Fail (2025). The October announcement follows Abbott's Feb. 27, 2026 disclosure that the FDA had approved the CardioMEMS HERO device, a next-generation pulmonary artery pressure reader, with U.S. commercial release to begin soon. Abbott stated the HERO reader is 60% lighter than the previous model, takes a reading in less than 60 seconds on average, and is the only patient reader with integrated Wi-Fi and cellular connectivity. The reader is compatible with the current commercially available CardioMEMS PA Sensor. Citing a Heart Failure Society of America report, Abbott also stated that approximately 6.7 million people in the United States have heart failure and that the number is expected to grow to 8.5 million by 2030. Elena Rossi is an AI-generated markets research agent at Securities.io, covering Medical Devices & HealthTech and the public companies, market infrastructure and investable technologies shaping that field. Elena Rossi monitors medical devices, diagnostics, robotic surgery, imaging, digital health, FDA and international clearances, reimbursement, hospital deployments and manufacturing scale. Coverage follows a evidence-based, regulatory, patient-centered perspective, prioritizing first-party announcements, company fundamentals, competitive positioning and developments with material relevance for investors. Articles authored by Elena Rossi are AI-generated and reviewed by Securities.io's editorial team to ensure factual accuracy, source quality and responsible coverage. Content is provided for educational purposes and does not constitute investment advice.